Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV

Lilian A Inocencio, Anderson A Pereira, Maria Cecilia A Sucupira, José Carlos C Fernandez, Célia P Jorge, Denise Fc Souza, Helena T Fink, Ricardo S Diaz, Irina M Becker, Theodoro A Suffert, Monica B Arruda, Olinda Macedo, Mariangela Bg Simão, Amilcar Tanuri, Lilian A Inocencio, Anderson A Pereira, Maria Cecilia A Sucupira, José Carlos C Fernandez, Célia P Jorge, Denise Fc Souza, Helena T Fink, Ricardo S Diaz, Irina M Becker, Theodoro A Suffert, Monica B Arruda, Olinda Macedo, Mariangela Bg Simão, Amilcar Tanuri

Abstract

Use of antiretrovirals is widespread in Brazil, where more than 200,000 individuals are under treatment. Although general prevalence of primary antiretroviral resistance in Brazil is low, systematic sampling in large metropolitan areas has not being performed.The HIV Threshold Survey methodology (HIV-THS, WHO) was utilized, targeting Brazil's four major regions and selecting the six most populated state capitals: Sao Paulo, Rio de Janeiro, Salvador, Porto Alegre, Brasilia and Belem. We were able to sequence samples from 210 individuals with recent HIV diagnosis, 17 of them (8.1%) carrying HIV isolates with primary antiretroviral resistance mutations. Five, nine and four isolates showed mutations related to resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), respectively. Using HIV-THS, we could find an intermediate level of transmitted resistance (5% to 15%) in Belem/Brasilia, Sao Paulo and Rio de Janeiro. Lower level of transmitted resistance (<5%) were observed in the other areas. Despite the extensive antiretroviral exposure and high rates of virologic antiretroviral failure in Brazil, the general prevalence of primary resistance is still low. However, an intermediate level of primary resistance was found in the four major Brazilian cities, confirming the critical need to start larger sampling surveys to better define the risk factors associated with transmission of resistant HIV.

References

    1. Teixeira PR, Vitória MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS. 2004;12(Suppl 3):5–7. doi: 10.1097/00002030-200406003-00002.
    1. Medeiros R, Diaz RS, Castelo A. Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis. 2002;12:298–304.
    1. Caseiro MM, Golegã AAC, Etzel A, Diaz RS. Characterization of virologic failure after an initially successful 48-week course of antiretroviral therapy in HIV/AIDS outpatients treated in Santos, Brazil. Brazilian Journal of Infectious Diseases. 2008;12:162–166. doi: 10.1590/S1413-86702008000300001.
    1. De Medeiros LB, Lacerda HR, Cavalcanti AM, De Albuquerque M de-F. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2006;12:845–849.
    1. Brígido LF, Nunes CC, Oliveira CM, Knoll RK, Ferreira JL, Freitas CA, Alves MA, Dias C, Rodrigues R. Research Capacity Program. HIV type 1 subtype C and CB Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS Res Hum Retroviruses. 2007;12:1579–1586. doi: 10.1089/aid.2007.0102.
    1. Chaix ML, Harzic M, Masquelier B, Pellegrin I, Meyer L, Costagliola DI, Rouzioux C, Brun-Vezinet F, Ac11 Resistance Group Cohort, Primo and Primoferon Study Groups. Prevalence of genotypic drug resistance among French patients infected during the year 1999. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago. 2001. pp. 2–4.
    1. Tamalet C, Pasquier C, Yahi N, Colson P, Martin LP, Lepeu G, Quinson AM, Poizot-Martin I, Dhiver C, Fantini J. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol. 2000;12:181–186. doi: 10.1002/(SICI)1096-9071(200006)61:2<181::AID-JMV2>;2-T.
    1. Duwe S, Brunn M, Altman D, Hamouda O, Schmidt B, Walter H, Pauli G, Kücherer C. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients from the German seroconverter study. J Acquir Immune Defic Syndr. 2001;12:266–273. doi: 10.1097/00042560-200103010-00010.
    1. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J. 2001;12:1087–1088. doi: 10.1136/bmj.322.7294.1087.
    1. Little SJ, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Conway B, Saag MS, Connick E, Holte S, Corey L, Keiser PH, Mwatha A, Dawson K, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. Antiviral Ther. 2001;12(Suppl 1):21.
    1. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;12:1135–1141. doi: 10.1001/jama.282.12.1135.
    1. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, Barile A, VanCott TC, Vahey MT, McCutchan FE, Birx DL, Richman DD, Mascola JR. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med. 1999;12:502–506.
    1. Briones C, Perez-Olmeda M, Rodriguez C, Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr. 2001;12:145–150. doi: 10.1097/00042560-200102010-00006.
    1. Weinstock H, Respess R, Heneine W, Petropoulos CJ, Hellmann S, Luo CC, Pau CP, Woods T, Gwinn M, Kaplan J. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconversters in the United States, 1993-1998. J Infect Dis. 2000;12:330–333. doi: 10.1086/315686.
    1. Zaidi I, Weinstock H, Woods T, Petropoulos CJ, Hellmann NS, Luo CC, Pau CP, Woods T, Gwinn M, Kaplan J. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1-infected persons in 10 US cities, 1997-2000. Antiviral Ther. 2001;12(Suppl 1):118.
    1. Puig T, Perez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gómez-Cano M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS. 2000;12:727–732. doi: 10.1097/00002030-200004140-00012.
    1. Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998;12:1015–1020. doi: 10.1097/00002030-199809000-00007.
    1. Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, Wainberg MA, Salomon H. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antiviral Ther. 2001;12:71–77.
    1. Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquire Immune Defic Syndr. 1999;12:401–405.
    1. Delgado E, Leon-Ponte M, Villahermosa ML, Cuevas MT, Deibis L, Echeverria G, Thomson MM, Pérez-Alvarez L, Osmanov S, Nájera R. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: A UNAIDS study. AIDS Res Hum Retroviruses. 2001;12:753–758. doi: 10.1089/088922201750237022.
    1. Brindeiro RM, Diaz RS, Sabino EC, Morgado MG, Pires IL, Brigido L, Dantas MC, Barreira D, Teixeira PR, Tanuri A. Brazilian Network for Drug Resistance Surveillance. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS. 2003;12:1063–1069. doi: 10.1097/00002030-200305020-00016.
    1. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, Vijver D van de, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;12:e4724. doi: 10.1371/journal.pone.0004724.
    1. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther. 2008;12(Suppl 2):37–48.
    1. Gonsalez CR, Alcalde R, Nishiya A, Barreto CC, Silva FE, de Almeida A, Mendonça M, Ferreira F, Fernandes SS, Casseb J, Duarte AJ. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city. Virus Res. 2007;12:87–90. doi: 10.1016/j.virusres.2007.06.021.
    1. Pires IL, Soares MA, Speranza FA, Ishii SK, Vieira MC, Gouvêa MI, Guimarães MA, de Oliveira FE, Magnanini MM, Brindeiro RM, Tanuri A. Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol. 2004;12:426–430. doi: 10.1128/JCM.42.1.426-430.2004.
    1. Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JL, Castro SM, Stella IM, Brigido LF. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res. 2006;12:201–217. doi: 10.1016/j.virusres.2005.10.004.
    1. Sucupira MC, Caseiro MM, Alves K, Tescarollo G, Janini LM, Sabino EC, Castelo A, Page-Shafer K, Diaz RS. High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS. 2007;12:116–128. doi: 10.1089/apc.2006.0079.
    1. Pedroso C, Queiroz AT, Alcântara LC, Drexler JF, Diaz RS, Weyll N, Brites C. High prevalence of primary antiretroviral resistance among HIV-1-infected adults and children in Bahia, a northeast state of Brazil. J Acquir Immune Defic Syndr. 2007;12:251–253. doi: 10.1097/QAI.0b013e318050d8b0.
    1. Eyer-Silva WA, Morgado MG. Autochthonous horizontal transmission of a CRF02_AG strain revealed by a human immunodeficiency virus type 1 diversity survey in a small city in inner state of Rio de Janeiro, Southeast Brazil. Mem Inst Oswaldo Cruz. 2007;12:809–815.
    1. Little SJ, Smith DM. HIV treatment decisions and transmitted drug resistance. Clin Infect Dis. 2005;12:233–235. doi: 10.1086/431215.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera